News

Makefield Therapeutics has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles, a new drug delivery

Keryx Biopharmaceuticals, (Keryx) has initiated Phase 3 registration clinical trial for KRX-0401 (perifosine), a PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, entitled, ‘A

Takeda Pharmaceutical (Takeda) and Pfizer have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in the country.

Neptune Technologies & Bioressources (Neptune) announces additional preclinical research results on its Acasti Pharma (Acasti) drug development program. Acasti announces the results of additional preclinical research designed to

The Medicines has reported that it is voluntarily recalling eleven lots of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has

Unilife Medical Solutions (Unilife) has signed agreements for the construction of its new global headquarters and commercial production facility in York, Pennsylvania. The medical device production facility will

EuroPharma has signed an exclusive multi-year contract with DolCas Biotech (DolCas) for the use of absorbency BCM-95 curcumin and specialised BosPure boswellia in multiple EuroPharma formulations. Reportedly, the

Advanced Life Sciences has reported positive top-line results from a pivotal, non-human primate study of its once-a-day, oral antibiotic Restanza (cethromycin) against an inhaled lethal dose of Tularemia.

Cellular Dynamics International (CDI) has launched iCell Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to aid